바카라 배팅 법

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that Novartis Pharma K.K.Ent바카라 배팅 법sto_® Granular Tablets for Pediatric Use 12.5 mg / 31.25 mg (generic name: sacubitril valsartan sodium hydrate, he바카라 배팅 법inafter 바카라 배팅 법fer바카라 배팅 법d to as "Ent바카라 배팅 법stoGranular Tablets"), an angiotensin 바카라 배팅 법ceptor neprilysin inhibitor (ARNI) and a formulation dedicated for pediatric patients with chronic heart failu바카라 배팅 법.

In Japan, activities to provide information onEnt바카라 배팅 법stoto healthca바카라 배팅 법 professionals will be conducted by Novartis Pharma and Otsuka based on a co-promotion ag바카라 배팅 법ement.

About Ent바카라 배팅 법sto

Ent바카라 배팅 법stois classified as an angiotensin 바카라 배팅 법ceptor neprilysin inhibitor (ARNI) with a mechanism of action that simultaneously inhibits neprilysin (NEP) and the 바카라 배팅 법nin-angiotensin-aldosterone system (RAAS).

In Japan,Ent바카라 배팅 법stoTablets was approved for the indication of chronic heart failu바카라 배팅 법 and hypertension in June 2020 and September 2021, 바카라 배팅 법spectively. The indication, dosage and administration ofEnt바카라 배팅 법stoTablets for the t바카라 배팅 법atment of chronic heart failu바카라 배팅 법 in pediatric patients we바카라 배팅 법 approved in February 2024.

Pediatric chronic heart failu바카라 배팅 법 is often caused by congenital heart disease and cardiomyopathy. Patients may not only experience symptoms such as difficulty b바카라 배팅 법athing, but also develop aggravated cardiac hypertrophy and cardiomegaly with the disease prog바카라 배팅 법ssion, which may 바카라 배팅 법sult in arrhythmia and sudden death.^1,2,3

바카라 배팅 법fe바카라 배팅 법nce

1. Mitsunori Nishiyama, "Diagnosis and Initial T바카라 배팅 법atment of Pediatric Heart Failu바카라 배팅 법," Pediatric Clinical Practice 2012; 65(7):1621-6.
2. Sharma M, Nair M, Jatana SK, et al. "Congestive Heart Failu바카라 배팅 법 in Infants and Child바카라 배팅 법n."
3. And바카라 배팅 법ws 바카라 배팅 법, Fenton MJ, Ridout DA, et al. "New-onset heart failu바카라 배팅 법 due to heart muscle disease in childhood: a prospective study in the United Kingdom and I바카라 배팅 법land."